Topic is suspended
Status Suspended
Process STA 2018
ID number 3782


Key events during the development of the guidance:

Date Update
15 September 2020 Suspended. Topic is suspended
15 September 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
01 April 2020 Topic has been proposed

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance